Checkpoint receptor blockers, known to act by blocking the pathways that inhibit immune
cell activation and stimulate immune responses against tumor cells, have been immensely …

T-cell receptor–engineered T-cell therapy and chimeric antigen receptor T-cell therapy are 2
types of adoptive T-cell therapy that genetically modify natural T cells to treat cancers …

Genome‐editing therapeutics are poised to treat human diseases. As we enter clinical trials
with the most promising CRISPR‐Cas9 and CRISPR‐Cas12a (Cpf1) modalities, the risks …

New approaches to cancer immunotherapy have been developed, showing the ability to
harness the immune system to treat and eliminate cancer. For many solid tumors, therapy …

CD4+ T cell activation promotes the pathogenic process of systemic lupus erythematosus
(SLE). T cell receptor (TCR) complex are highly core fucosylated glycoproteins, which play …

G protein-coupled receptors (GPCRs) belong to a large superfamily of membrane receptors
mediating a variety of physiological functions. As such they are attractive targets for drug …

T-cell receptors (TCR) mediate immune responses recognizing peptides in complex with
major histocompatibility complexes (pMHC) displayed on the surface of cells. Resolving the …

For successful application of chimeric antigen receptor (CAR) T cell therapy in solid tumors,
major hurdles have to be overcome. CAR T cells have to cross the vascular barrier, which is …

How T-cell receptors (TCRs) can be intrinsically biased toward MHC proteins while
simultaneously display the structural adaptability required to engage diverse ligands …

Antigen recognition of peptide-major histocompatibility complexes (pMHCs) by T cells, a key
step in initiating adaptive immune responses, is performed by the T cell receptor (TCR) …